Importantly, a recent follow-up study of the ABCSG-18 trial confirmed the that blocking RANKL in an adjuvant breast cancer therapy setting not only markedly reduces the risk of breaking bones but also significantly reduces the reoccurrence of the breast tumors (152, 153). This evidence concerns the gene TNFSF11 and breast cancer.